Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Davies M, Færch L, Jeppesen OK, et al. The Lancet 2021;397:971-984.
What it found
Mean body weight change of -9.6% with 2.4 mg vs -3.4% with placebo; 68.8% vs 28.5% lost at least 5%. Gastrointestinal events were reported by 63.5% (2.4 mg), 57.5% (1.0 mg) and 34.3% (placebo), mostly mild to moderate.
Limitations
Weight loss was smaller than in people without diabetes (STEP 1). All groups had lifestyle intervention. Results after stopping were not studied.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.